STOCK TITAN

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

MediciNova (NASDAQ: MNOV) announced it will receive monetary damages following the settlement of Sanofi-Novartis litigation. The company plans to use this non-dilutive funding to support ongoing clinical development programs, particularly focusing on their late-stage pipeline targeting inflammatory, metabolic, and neurodegenerative diseases. The settlement validates MediciNova's intellectual property value and strengthens their financial position as they advance their novel small molecule therapies towards commercialization.

MediciNova (NASDAQ: MNOV) ha annunciato che riceverà un risarcimento monetario a seguito della risoluzione della controversia legale tra Sanofi e Novartis. L'azienda prevede di utilizzare questo finanziamento non diluitivo per sostenere i programmi di sviluppo clinico in corso, concentrandosi particolarmente sul loro pipeline in fase avanzata che mira a malattie infiammatorie, metaboliche e neurodegenerative. L'accordo convalida il valore della proprietà intellettuale di MediciNova e rafforza la loro posizione finanziaria mentre avanzano le loro terapie innovative a piccole molecole verso la commercializzazione.

MediciNova (NASDAQ: MNOV) anunció que recibirá compensaciones monetarias tras el acuerdo del litigio entre Sanofi y Novartis. La compañía planea utilizar este financiamiento no dilutivo para apoyar los programas de desarrollo clínico en curso, enfocándose especialmente en su pipeline en etapa avanzada que tiene como objetivo enfermedades inflamatorias, metabólicas y neurodegenerativas. El acuerdo valida el valor de la propiedad intelectual de MediciNova y refuerza su posición financiera a medida que avanza en sus nuevas terapias de pequeñas moléculas hacia la comercialización.

메디시노바 (NASDAQ: MNOV)는 사노피-노바르티스 소송의 합의에 따라 금전적 손해를 받게 될 것이라고 발표했습니다. 이 회사는 이 희석되지 않는 자금을 사용하여 현재 진행 중인 임상 개발 프로그램을 지원할 계획이며, 특히 염증, 대사 및 신경퇴행성 질환을 표적으로 하는 후기 단계 파이프라인에 집중할 것입니다. 이번 합의는 메디시노바의 지적 재산 가치를 검증하고, 그들이 상업화로 나아가면서 재정적 위치를 강화합니다.

MediciNova (NASDAQ: MNOV) a annoncé qu'elle recevra des dommages-intérêts monétaires à la suite du règlement du litige entre Sanofi et Novartis. La société prévoit d'utiliser ce financement non dilutif pour soutenir ses programmes de développement clinique en cours, en se concentrant particulièrement sur son pipeline avancé ciblant les maladies inflammatoires, métaboliques et neurodégénératives. Le règlement valide la valeur de la propriété intellectuelle de MediciNova et renforce leur position financière alors qu'ils avancent leurs nouvelles thérapies à petites molécules vers la commercialisation.

MediciNova (NASDAQ: MNOV) gab bekannt, dass sie monetäre Schadensersatzansprüche nach der Einigung im Rechtsstreit zwischen Sanofi und Novartis erhalten wird. Das Unternehmen plant, diese nicht verwässernde Finanzierung zur Unterstützung der laufenden klinischen Entwicklungsprogramme zu verwenden, wobei der Schwerpunkt auf ihrem fortgeschrittenen Pipeline liegt, die sich auf entzündliche, metabolische und neurodegenerative Erkrankungen konzentriert. Die Einigung validiert den Wert des geistigen Eigentums von MediciNova und stärkt deren finanzielle Position, während sie ihre neuartigen kleinen Molekültherapien in Richtung Kommerzialisierung vorantreiben.

Positive
  • Will receive monetary damages from Sanofi-Novartis litigation settlement
  • Secured non-dilutive funding for clinical development programs
  • Validation of company's intellectual property value
Negative
  • None.

Insights

This patent settlement represents a significant positive development for MediciNova, particularly given its relatively small market cap of $78.2M. The incoming non-dilutive funding will strengthen the company's balance sheet without requiring additional share issuance that would dilute existing shareholders. While the exact monetary amount remains undisclosed, any substantial settlement could materially impact the company's financial position and ability to advance its late-stage pipeline.

The settlement validates MediciNova's intellectual property portfolio and could potentially lead to future monetization opportunities. The company's prudent financial management approach, combined with this unexpected cash infusion, should help extend their operational runway for clinical development programs. This is especially valuable for small-cap biotech companies where cash preservation is important for long-term survival and development progress.

LA JOLLA, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it was notified by Sanofi that the Sanofi/Novartis litigation was settled. Accordingly, MediciNova is entitled to receive a certain amount of monetary damages through this settlement. Further details will be provided as they become available.

Yuichi Iwaki, M.D., Ph.D., MediciNova CEO commented, “The successful resolution of the Sanofi-Novartis litigation and the resulting monetary damages due to MediciNova both validates the value of our intellectual property and provides an additional source of non-dilutive funding, which we plan to apply to supporting our ongoing clinical development programs, particularly our late-stage pipeline targeting inflammatory, metabolic, and neurodegenerative diseases. This outcome further reinforces our commitment to developing unique assets with long-term value.  We remain dedicated to preserving our financial position as we continue to prudently advance our novel small molecule therapies towards commercialization."

About Sanofi/Novartis litigation

On March 30,2022, MediciNova, Inc. was notified that Genzyme Corporation, a subsidiary of Sanofi, filed its First Amended Complaint, which included a claim for infringement of U.S. Patent No. 9,051,542, on February 23, 2022 in a lawsuit previously filed against Novartis Gene Therapies, Inc., Novartis Pharmaceutical Corporation, and Novartis AG in the U.S. District Court for the District of Delaware. This patent, among others was included in the assignment Agreement dated December 19, 2005, between MediciNova, Inc., as successor in interest to Avigen, Inc. and Genzyme Corporation. The plaintiffs allege that the defendants infringe certain U.S. patents through the unauthorized manufacture, use, and sale of recombinant adeno-associated virus vectors (“rAAV vectors”) for their gene therapy drug Zolgensma. If Genzyme recovers any monetary damages, by way of settlement or otherwise, as a result of this litigation, then MediciNova is entitled to receive a certain portion of such monetary damages from Genzyme as per the terms of assignment agreement.

About Zolgensma

The U.S. Food and Drug Administration (FDA) approved Zolgensma (onasemnogene abeparvovec-xioi) on May 24, 2019. Zolgensma is a gene therapy that treats children under two years old with spinal muscular atrophy (SMA). It was the first gene therapy approved by the FDA to treat a disease. Novartis priced an infusion at $2.1 million, making it one of the priciest medicines on the market. Zolgensma has become one of Novartis’ top-sellers, generating more than $1.3 billion in annual sales in 2023. The company expects it to eventually earn between $1.5 billion and $2 billion annually. Approved in 45 countries, Zolgensma replaces the faulty gene responsible for causing spinal muscular atrophy, a condition that in its severe form robs infants of the ability to stand, sit and, eventually, breathe. Untreated, it’s typically fatal by a very young age. Zolgensma can deliver dramatic benefits, keeping children alive and in some cases helping them achieve motor and developmental milestones they otherwise wouldn’t. In the U.S, its use is limited to babies under the age of two, where it’s seen as having the greatest benefit. 

About MediciNova

MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN 001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by, or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2023 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

INVESTOR CONTACT:

David H. Crean, Ph.D.
Chief Business Officer
MediciNova, Inc
info@medicinova.com


FAQ

What monetary settlement did MediciNova (MNOV) receive from Sanofi-Novartis in November 2024?

The specific amount of monetary damages was not disclosed in the announcement. MediciNova stated that further details would be provided as they become available.

How will MediciNova (MNOV) use the settlement money from Sanofi-Novartis?

MediciNova plans to use the settlement funds as non-dilutive funding to support their ongoing clinical development programs, particularly their late-stage pipeline targeting inflammatory, metabolic, and neurodegenerative diseases.

What impact did the Sanofi-Novartis settlement have on MediciNova's (MNOV) intellectual property?

The settlement validated the value of MediciNova's intellectual property and provided additional non-dilutive funding for the company's clinical development programs.

Medicinova, Inc.

NASDAQ:MNOV

MNOV Rankings

MNOV Latest News

MNOV Stock Data

106.92M
47.58M
2.98%
21.3%
0.37%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
LA JOLLA